Abstract
Objective: To assess the effectiveness of multimodal infection control interventions in the prevention of SARS−CoV−2 infections in healthcare professionals. Design: Sequential follow−up study. Setting: Largest tertiary care centre in northern Germany. Participants: 1253 employees of the University Medical Center Hamburg−Eppendorf were sequentially assessed for the presence of SARS−CoV−2 IgG antibodies at the beginning of the covid−19 epidemic (20 March − 9 April), one month (20 April − 8 May), and another two months later (22 June − 24 July). Of those, 1026 were healthcare workers (HCWs) of whom 292 were directly involved in the care of covid−19 patients. During the study period, infection control interventions were deployed, those included i) strict barrier nursing of all known covid−19 patients including FFP2 (N95) masks, goggles, gloves, hoods and protective gowns, ii) visitor restrictions with access control at all hospital entries, iii) mandatory wearing of disposable face masks in all clinical settings, and iv) universal RT−PCR admission screening of patients. Main Outcome Measures: SARS−CoV−2 IgG seroconversion rate. Results: At the initial screening, ten participants displayed significant IgG antibody ratios. Another ten individuals showed seroconversion at the second time point one month later, only two further participants seroconverted during the subsequent two months. The overall SARS−CoV−2 seroprevalence in the study cohort at the last follow−up was 1.8%, the seroconversion rate dropped from 0.81% to 0.08% per month despite a longer observation period. Amongst HCWs seropositivity was increased in those directly involved in the care of patients with SARS−CoV−2 infections (3.8%, n=11) compared to other HCWs (1.4%, n=10, P=0.025). However, after the adoption of all multimodal infection control interventions seroconversions were observed in only two more HCWs, neither of whom were involved in inpatient care. Conclusion: Multimodal infection control and prevention interventions are highly effective in mitigating SARS−CoV−2 infections of healthcare professionals.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: AWL had a material transfer agreement with Euroimmun GmbH, which included ten ELISA plates as well as technical help provided by the company when setting up the newly established ELISA. All other authors declare no support from any organisation for the submitted work. All authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Ethics Committee of the Medical Council of Hamburg (PV 7298). Written informed consent was obtained by all study participants prior to enrolment.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 2 revised
Data Availability
No additional data available.
